Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02226120

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction Clinical Trial

Official title:
A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Clinical Trial Summary

The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Chronic Heart Failure With Reduced Ejection Fraction
  • Heart Failure
Clinical Trial Details
NCT number NCT02226120
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date October 16, 2014
Completion date December 28, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT02861534 - A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Phase 3
Recruiting NCT06148935 - An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
Active, not recruiting NCT05093933 - A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) Phase 3
Completed NCT04836182 - A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Recruiting NCT04983043 - Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure Phase 2
Completed NCT04840914 - A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 1
Completed NCT02768298 - Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Phase 4
Active, not recruiting NCT05974189 - The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
Recruiting NCT05553886 - S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction Phase 3
Completed NCT02900378 - randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure Phase 3
Withdrawn NCT04464525 - Omecamtiv Mecarbil Post-trial Access Study Phase 3
Recruiting NCT05658458 - A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction) Phase 4
Recruiting NCT05728502 - An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
Recruiting NCT06195930 - A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Active, not recruiting NCT06363110 - An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States